Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iDoc: E-Prescribing Gains Momentum, But Roadblocks Remain

This article was originally published in RPM Report

Executive Summary

New e-prescribing standards under Medicare Part D were finalized in April, but doctors aren't rushing to swap their pen and pad for a PDA. However, a bill floating through Congress may jumpstart adoption of the technology by doctors--if the legislation can get into this year's Medicare bill.

You may also be interested in...



Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Medicare Rx in 2009: Re-Politicizing Drug Prices

Remember when the Democrats took over Congress and promised to do something about prescription drug prices under Part D? They didn't get very far, and they haven't been talking about it since. But when beneficiaries get ready to renew their Part D coverage in 2009-and see how much their costs are going up-there may be a lot more to talk about.

Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year

United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel